TIDMVRP
RNS Number : 0681E
Verona Pharma PLC
03 May 2017
Grant of Options and RSUs and PDMR Dealings
May 3, 2017, LONDON - Verona Pharma plc (AIM: VRP) ("Verona
Pharma"), a clinical-stage biopharmaceutical company focused on
developing and commercialising innovative therapeutics for the
treatment of respiratory diseases with significant unmet needs,
announces that it granted the following options over ordinary
shares of GBP0.05 each (the "Ordinary Shares") and American
Depositary Shares ("ADS") and restricted share units ("RSUs") and
Restricted American Depositary Share Units ("RADSUs") to directors
and employees of Verona Pharma under and in accordance with Verona
Pharma's 2017 Incentive Award Plan:
-- 3,430,316 options to purchase Ordinary Shares;
-- 129,564 options to purchase ADSs representing 1,036,512 Ordinary Shares;
-- 853,220 RSUs; and
-- 24,877 RADSUs representing 199,016 Ordinary Shares.
Each RSU and RADSU represents an unfunded, unsecured right to
receive, on the applicable settlement date, one Ordinary Share or
the equivalent number of ADSs, as applicable, or an amount in cash
or other consideration. Except where the context indicates
otherwise, references hereunder to the Ordinary Shares shall be
deemed to include a number of ADSs equal to an Ordinary Share. No
consideration was paid in respect of the grant of awards.
PDMR Dealings
Verona Pharma notifies the following transactions by persons
discharging managerial responsibilities ("PDMRs") in its Ordinary
Shares through the grant of options over Ordinary Shares and ADSs
and RSUs under and in accordance with Verona Pharma's 2017
Incentive Award Plan.
Name Options over RSUs and RADSUs
----------------------- ---------------------------------------- -----------------------------
Dr Jan-Anders Karlsson 1,385,598 Ordinary Shares 346,395 RSUs
----------------------- ---------------------------------------- -----------------------------
Vikas Sinha 15,048 ADSs -
(Representing 120,384 Ordinary Shares)
----------------------- ---------------------------------------- -----------------------------
Piers Morgan 802,690 Ordinary Shares 200,669 RSUs
----------------------- ---------------------------------------- -----------------------------
Ken Newman 99,516 ADSs 24,877 RADSUs
(Representing 796,128 Ordinary Shares) (Representing 199,016 RSUs)
----------------------- ---------------------------------------- -----------------------------
The options over Ordinary Shares have an exercise price of
GBP1.32 per Ordinary Share. The options over ADSs have an exercise
price of GBP10.56 per ADS. The RSUs have a value of GBP1.32 per RSU
and the RADSUs have a value of GBP10.56 per RADSU.
The options, RSUs and RADSUs set forth in the table above (other
than those granted to Mr Sinha) will vest as to 50% of the Ordinary
Shares or ADSs (as appropriate) in three substantially equal annual
instalments following the grant date and as to 50% of the Ordinary
Shares or ADSs (as appropriate) in four substantially equal annual
instalments following the grant date. The options granted to Mr
Sinha will vest in three substantially equal annual instalments
following the grant date.
The notification of dealing form in respect of option/RSU awards
for each PDMR can be found below.
For further information please contact:
Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief info@veronapharma.com
Executive Officer
N+1 Singer (Nominated Tel: +44 (0)20 7496 3000
Adviser and UK Broker)
Aubrey Powell / James
White
FTI Consulting (UK Media Tel: +44 (0)20 3727 1000
and Investor Enquiries)
Simon Conway / Stephanie veronapharma@fticonsulting.com
Cuthbert /
Natalie Garland-Collins
ICR, Inc. (US Media and
Investor Enquiries)
James Heins Tel: +1 203-682-8251
James.Heins@icrinc.com
Stephanie Carrington Tel: +1 646-277-1282
Stephanie.Carrington@icrinc.com
1 Details of the person discharging managerial
responsibilities / person closely associated
--- -------------------------------------------------------------------
a) Name Dr Jan-Anders Karlsson
--- ------------------------ -----------------------------------------
2 Reason for the notification
--- -------------------------------------------------------------------
a) Position/status Chief Executive Officer
--- ------------------------ -----------------------------------------
b) Initial notification Initial Notification
/Amendment
--- ------------------------ -----------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- -------------------------------------------------------------------
a) Name Verona Pharma plc
--- ------------------------ -----------------------------------------
b) Legal Entity 213800EVI6O6J3TIAL06
Identifier
--- ------------------------ -----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- -------------------------------------------------------------------
a) Description of Ordinary shares of 5p each
the financial
instrument, type
of instrument
Identification ISIN Code: GB00BYW2KH80
code
--- ------------------------ -----------------------------------------
b) Nature of the Issue of options over Ordinary
transaction Shares
--- ------------------------ -----------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) ---------------- --------------------
Exercise Price: Options over
GBP1.32 1,385,598 Ordinary
Shares
---------------- --------------------
--- ------------------------ -----------------------------------------
d) Aggregated information N/a (single transaction)
- Aggregated
volume
- Price
--- ------------------------ -----------------------------------------
e) Date of the transaction 26 April 2017
--- ------------------------ -----------------------------------------
f) Place of the London Stock Exchange, AIM
transaction
--- ------------------------ -----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- -------------------------------------------------------------------
a) Description of Ordinary shares of 5p each
the financial
instrument, type
of instrument
---
Identification ISIN Code: GB00BYW2KH80
code
--- ------------------------ -----------------------------------------
b) Nature of transaction Grant of RSUs, each of which
represents an unfunded, unsecured
right to receive, on the applicable
settlement date, one Ordinary
Share or an amount in cash or
other consideration
--- ------------------------ -----------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) ------------------ ----------
No consideration 346,395
------------------ ----------
--- ------------------------ -----------------------------------------
d) Aggregated information N/a (single transaction)
- Aggregated
volume
- Price
--- ------------------------ -----------------------------------------
e) Date of the transaction 28 April 2017
--- ------------------------ -----------------------------------------
f) Place of the London Stock Exchange, AIM
transaction
--- ------------------------ -----------------------------------------
1 Details of the person discharging managerial
responsibilities / person closely associated
--- -----------------------------------------------------------------
a) Name Vikas Sinha
--- ------------------------ ---------------------------------------
2 Reason for the notification
--- -----------------------------------------------------------------
a) Position/status Non-Executive Director
--- ------------------------ ---------------------------------------
b) Initial notification Initial Notification
/Amendment
--- ------------------------ ---------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- -----------------------------------------------------------------
a) Name Verona Pharma plc
--- ------------------------ ---------------------------------------
b) Legal Entity 213800EVI6O6J3TIAL06
Identifier
--- ------------------------ ---------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- -----------------------------------------------------------------
a) Description of American Depositary Shares ("ADSs"),
the financial representing ordinary shares
instrument, type of 5p each, on deposit with
of instrument a U.S. banking institution selected
by the Company and which are
registered pursuant to a Form
F-6.
Identification ISIN Code: US9250501064
code
--- ------------------------ ---------------------------------------
b) Nature of the Issue of options over ADSs
transaction
--- ------------------------ ---------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) ---------------- ------------------
Exercise Price: Options over
GBP10.56 15,048 ADSs
(representing
120,384 Ordinary
Shares)
---------------- ------------------
--- ------------------------ ---------------------------------------
d) Aggregated information N/a (single transaction)
- Aggregated
volume
- Price
--- ------------------------ ---------------------------------------
e) Date of the transaction 26 April 2017
--- ------------------------ ---------------------------------------
f) Place of the NASDAQ
transaction
--- ------------------------ ---------------------------------------
1 Details of the person discharging managerial
responsibilities / person closely associated
--- -----------------------------------------------------------------
a) Name Piers Morgan
--- ------------------------ ---------------------------------------
2 Reason for the notification
--- -----------------------------------------------------------------
a) Position/status Chief Financial Officer
--- ------------------------ ---------------------------------------
b) Initial notification Initial Notification
/Amendment
--- ------------------------ ---------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- -----------------------------------------------------------------
a) Name Verona Pharma plc
--- ------------------------ ---------------------------------------
b) Legal Entity 213800EVI6O6J3TIAL06
Identifier
--- ------------------------ ---------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- -----------------------------------------------------------------
a) Description of Ordinary shares of 5p each
the financial
instrument, type
of instrument
Identification ISIN Code: GB00BYW2KH80
code
--- ------------------------ ---------------------------------------
b) Nature of the Issue of options over Ordinary
transaction Shares
--- ------------------------ ---------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) ---------------- ------------------
Exercise Price: Options over
GBP1.32 802,690 Ordinary
Shares
---------------- ------------------
--- ------------------------ ---------------------------------------
d) Aggregated information N/a (single transaction)
- Aggregated
volume
- Price
--- ------------------------ ---------------------------------------
e) Date of the transaction 26 April 2017
--- ------------------------ ---------------------------------------
f) Place of the London Stock Exchange, AIM
transaction
--- ------------------------ ---------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- -----------------------------------------------------------------
a) Description of Ordinary shares of 5p each
the financial
instrument, type
of instrument
---
Identification ISIN Code: GB00BYW2KH80
code
--- ------------------------ ---------------------------------------
b) Nature of transaction Grant of RSUs, each of which
represents an unfunded, unsecured
right to receive, on the applicable
settlement date, one Ordinary
Share or an amount in cash or
other consideration
--- ------------------------ ---------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) ------------------ ----------
No consideration 200,669
------------------ ----------
--- ------------------------ ---------------------------------------
d) Aggregated information N/a (single transaction)
- Aggregated
volume
- Price
--- ------------------------ ---------------------------------------
e) Date of the transaction 28 April 2017
--- ------------------------ ---------------------------------------
f) Place of the London Stock Exchange, AIM
transaction
--- ------------------------ ---------------------------------------
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ------------------------------------------------------------------------
a) Name Ken Newman
--- ------------------------ ----------------------------------------------
2 Reason for the notification
--- ------------------------------------------------------------------------
a) Position/status Chief Medical Officer
--- ------------------------ ----------------------------------------------
b) Initial notification Initial Notification
/Amendment
--- ------------------------ ----------------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- ------------------------------------------------------------------------
a) Name Verona Pharma plc
--- ------------------------ ----------------------------------------------
b) Legal Entity 213800EVI6O6J3TIAL06
Identifier
--- ------------------------ ----------------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- ------------------------------------------------------------------------
a) Description of American Depositary Shares ("ADSs"),
the financial representing ordinary shares
instrument, type of 5p each, on deposit with
of instrument a U.S. banking institution selected
by the Company and which are
registered pursuant to a Form
F-6.
Identification ISIN Code: GB00BYW2KH80
code
--- ------------------------ ----------------------------------------------
b) Nature of the Issue of options over ADSs
transaction
--- ------------------------ ----------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) ----------------- -----------------------
Exercise Options over 99,516
Price: GBP10.56 ADSs
(representing 796,128
Ordinary Shares)
----------------- -----------------------
--- ------------------------ ----------------------------------------------
d) Aggregated information N/a (single transaction)
- Aggregated
volume
- Price
--- ------------------------ ----------------------------------------------
e) Date of the transaction 26 April 2017
--- ------------------------ ----------------------------------------------
f) Place of the NASDAQ
transaction
--- ------------------------ ----------------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
--- ------------------------------------------------------------------------
a) Description of ADSs
the financial
instrument, type
of instrument
---
Identification ISIN Code: US9250501064
code
--- ------------------------ ----------------------------------------------
b) Nature of transaction Grant of RADSUs, each of which
represents an unfunded, unsecured
right to receive, on the applicable
settlement date, one ADS or
an amount in cash or other consideration
--- ------------------------ ----------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) ----------------- ------------------------
No consideration 24,877
(representing 199,016
Ordinary Shares)
----------------- ------------------------
--- ------------------------ ----------------------------------------------
d) Aggregated information N/a (single transaction)
- Aggregated
volume
- Price
--- ------------------------ ----------------------------------------------
e) Date of the transaction 28 April 2017
--- ------------------------ ----------------------------------------------
f) Place of the NASDAQ
transaction
--- ------------------------ ----------------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHAJMBTMBJMBTR
(END) Dow Jones Newswires
May 03, 2017 07:34 ET (11:34 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024
